Jazz Pharmaceuticals (JAZZ) Expected to Announce Earnings on Monday

Key Points

• Jazz Pharmaceuticals is expected to report Q3 2026 earnings after the market closes on November 2. Analysts anticipate earnings of $6.26 per share on $1.21 billion in revenue.
• In its previous quarter, Jazz reported $5.71 in EPS, missing estimates, while revenue reached $1.21 billion and rose 15.5% year over year.
• Analysts remain bullish on the stock: Jazz has an average “Buy” rating and a consensus price target of $290.85, although insiders sold approximately $24.9 million of shares over the past three months.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of $6.26 per share and revenue of $1.21 billion for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The firm's revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter last year, the company posted ($8.25) earnings per share. On average, analysts expect Jazz Pharmaceuticals to post $18.24 EPS for the current fiscal year and $21.91 EPS for the next fiscal year.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $214.00 on Monday. The firm's 50-day moving average price is $236.11 and its 200-day moving average price is $233.16. The firm has a market capitalization of $13.89 billion, a price-to-earnings ratio of 14.76, a PEG ratio of 0.26 and a beta of 0.37. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a 1-year low of $128.80 and a 1-year high of $266.38.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares in the company, valued at approximately $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total value of $486,060.00. Following the completion of the sale, the chief executive officer directly owned 143,394 shares in the company, valued at approximately $34,849,043.82. This represents a 1.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 100,121 shares of company stock worth $24,855,802 over the last three months. Company insiders own 4.10% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on JAZZ shares. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a "buy" rating in a report on Wednesday, August 26th. Citigroup assumed coverage on Jazz Pharmaceuticals in a report on Wednesday, September 30th. They set a "buy" rating and a $325.00 target price on the stock. UBS Group increased their target price on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a "buy" rating in a research report on Friday, September 11th. Wells Fargo & Company raised their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an "overweight" rating in a research note on Tuesday, August 4th. Finally, TD Cowen lifted their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Buy" and an average price target of $290.85.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.